Arch

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Mardi, avril 16, 2024
Pillar, Phase, Patient, Reperfusion, Kidney, Inflammation, Arch, Hospital, Randomness, OTCQB, Science Advances, IRI, TMX Group, Kidney disease, Research, Acute kidney injury, Ischemia, Yolo Bypass, Oxygen, Liver, User experience, Unity Health Toronto, Injury, Regeneration, Placebo-controlled study, AKI, Ethics, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no therapeutic treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Arch Resources to Announce First Quarter 2024 Results on April 25

Retrieved on: 
Mercredi, avril 17, 2024
Arch Resources, Multimedia, Arch, PR Newswire

ST. LOUIS, April 17, 2024 /PRNewswire/ -- Arch Resources, Inc. (NYSE: ARCH) will discuss its first quarter 2024 financial results in an investor conference call on Thursday, April 25, 2024 at 10:00 a.m. Eastern time.

Key Points: 
  • ST. LOUIS, April 17, 2024 /PRNewswire/ -- Arch Resources, Inc. (NYSE: ARCH) will discuss its first quarter 2024 financial results in an investor conference call on Thursday, April 25, 2024 at 10:00 a.m. Eastern time.
  • The call will also be webcast and will be accessible via the "investor" section of the Arch website at http://investor.archrsc.com .
  • Arch's first quarter 2024 earnings release will be distributed via PR Newswire before the market opens on April 25 and will be posted to the company's website at that time.
  • Arch Resources is a premier producer of high-quality metallurgical products for the global steel industry.

Waterfront Toronto Announces Destination Art Piece for Sherbourne Common

Retrieved on: 
Jeudi, avril 4, 2024
Sherbourne Common, Atmosphere, Arch, Tourism, Spadina—Fort York, Industrial design

This installation demonstrates the impact of Waterfront Toronto's public art program and will solidify Toronto's waterfront as a destination for innovative and community-enhancing artwork.

Key Points: 
  • This installation demonstrates the impact of Waterfront Toronto's public art program and will solidify Toronto's waterfront as a destination for innovative and community-enhancing artwork.
  • This installation will be the destination piece within the East Bayfront Master Public Art Plan complementing existing art pieces in East Bayfront, including LIGHTKEEPER in Aitken Place Park and Light Showers in Sherbourne Common North.
  • Waterfront Toronto's public art program supports the revitalization of the waterfront by enhancing the cultural vibrancy and helping create complete communities.
  • "We're excited to bring Unfinished Arch to the waterfront as the centerpiece of Waterfront Toronto's public art master plan for East Bayfront.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Mercredi, avril 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Lundi, mars 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Vendredi, mars 15, 2024
Libin Cardiovascular Institute, Kidney, User experience, Assistant, AKI, Patient, Kidney disease, Inflammation, Hospital, TMX Group, Acute kidney injury, University, Ischemia, Injury, Dispute board, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Division, Phase, OTCQB, Liver, Yolo Bypass, Randomness, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • “We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .

Arch Capital Group Ltd. Releases 2023 Sustainability Reports

Retrieved on: 
Jeudi, avril 4, 2024
Sustainability, Professional Services, Insurance, Environment, Community, ESG, Thought, ACGL, Risk management, History, Arch, Capital Group Companies

Arch Capital Group Ltd. (NASDAQ: ACGL, Arch, the Company) today announced it has released its 2023 Sustainability Report, Sustainability Accounting Standards Board Report and Task Force for Climate-related Financial Disclosures.

Key Points: 
  • Arch Capital Group Ltd. (NASDAQ: ACGL, Arch, the Company) today announced it has released its 2023 Sustainability Report, Sustainability Accounting Standards Board Report and Task Force for Climate-related Financial Disclosures.
  • These three reports detail Arch’s environmental, social and governance (ESG) strategy, as well as the five key impact areas that support and drive the Company’s ESG initiatives: Business, Operations, Investments, People and Communities.
  • Organized under these pillars, Arch tracks sustainable progress and celebrates collaborative successes across the enterprise.
  • I’m proud of the progress that we’ve made to incorporate sustainability-driven thinking into core areas of our business and strengthen our ESG priorities.”
    To learn more about ESG at Arch, or to download a copy of these reports, visit https://www.archgroup.com/sustainability-governance/ .

Arch Introduces Participant Accident Coverage for Camps and Child Education Centers Through the Arch APEX℠ Platform

Retrieved on: 
Jeudi, mars 28, 2024
Insurance, Professional Services, APEX, SVP, Organization, Risk management, Sport, Child, Arch

Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX℠ digital platform.

Key Points: 
  • Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX℠ digital platform.
  • Participant Accident coverage is now available for child education centers, child development centers, nursery schools, preschools and after-school programs.
  • Jim Villa, SVP of Arch Accident & Health, commented on the launch: "Recognizing the specific insurance needs of camps and child education centers, particularly concerning accident protection for participants, is paramount.
  • For additional information on how this Participant Accident coverage can benefit camps, childcare services or other organizations, please visit the Arch website at https://www.archaccidenthealth.com/solutions/affinity-groups/participant... or reach out to our dedicated team at 855-951-2328.

Arch Reinsurance Group Announces Three Senior Promotions

Retrieved on: 
Mercredi, mars 13, 2024
Professional Services, Insurance, Finance, Growth, Arch, CFO

Arch Reinsurance Group (the Company) today announces the promotions of three senior executives, effective April 1, 2024: Jerome Halgan, Vanessa Hardy Pickering and Lester Pun.

Key Points: 
  • Arch Reinsurance Group (the Company) today announces the promotions of three senior executives, effective April 1, 2024: Jerome Halgan, Vanessa Hardy Pickering and Lester Pun.
  • Details of the promotions are as follows:
    Jerome Halgan will be President and Chief Underwriting Officer of Arch Reinsurance Group, in addition to maintaining his role as CEO of Arch Reinsurance Ltd. (Arch Re Ltd.).
  • Vanessa Hardy Pickering will be Chief Financial Officer (CFO) of Arch Reinsurance Group.
  • He joined Arch in 2018 and most recently served as Chief Actuary of Arch Re Ltd.
    “I am thrilled to announce Jerome, Vanessa and Lester’s well-earned promotions and to celebrate their contributions to Arch Re’s success,” said Maamoun Rajeh, Chairman and CEO of Arch Reinsurance Group.

McDonald's Announces Changes to Board of Directors; Enrique "Rick" Hernandez, Jr., Retires After a Distinguished 28 Years on the Board, Including Eight Years As Chairman

Retrieved on: 
Mardi, mars 19, 2024
MCD, Friends, Kimberly-Clark, Growth, McDonald's, Lead, Retirement, Arch, Management

CHICAGO, March 19, 2024 /PRNewswire/ -- McDonald's Corporation (NYSE: MCD) today announced the retirement of Enrique "Rick" Hernandez, Jr. as non-executive Chairman of the company's Board of Directors, effective as of the date of the Company's 2024 Annual Shareholders' Meeting. Following Rick's retirement, Chris Kempczinski will assume the combined role of Chief Executive Officer and Chairman of the Board, and Miles White will assume the role of Lead Independent Director. 

Key Points: 
  • The Company also announced the nomination of Mike Hsu, Chairman and Chief Executive Officer of Kimberly-Clark Corporation, as an independent director of the Board.
  • "As I reflect on my tenure with McDonald's, I'm inspired by the remarkable leaders with whom I've had the privilege to serve.
  • During his 28 years of service on the Board, McDonald's has delivered over 2,000% in total shareholder return.
  • "Rick has been a tremendous advisor to McDonald's since joining the Board in 1996, including serving alongside eight McDonald's CEOs.